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Aim: To investigate changes in body weight trajectories after the addition of individual sulpho-
nylureas (SUs) to metformin in patients with type 2 diabetes.
Materials and methods: We conducted a retrospective observational cohort study, in a primary
care setting in the Netherlands. Patients aged ≥18 years with type 2 diabetes who were included
in the ZODIAC cohort between 1998 and 2012 and who received metformin monotherapy at
inclusion (n = 29 195), and had used metformin as monotherapy for at least 1 year before receiv-
ing dual therapy through the addition of an SU for at least 1 year were eligible for inclusion. The
primary outcome was within-drug yearly change in body weight after receiving add-on therapy
with individual SUs during 5 years of follow-up. The secondary outcome was within-drug yearly
change in glycated haemoglobin (HbA1c). Annual changes in weight and HbA1c were estimated
with linear mixed models, adjusted for age, gender and diabetes duration.
Results: A total of 2958 patients were included. No signiﬁcant weight changes were observed
within and between any of the individual SUs after treatment intensiﬁcation (p = 0.24). In addi-
tion, no signiﬁcant difference in weight between the add-on therapy combinations was
observed (p = 0.26). The average HbA1c the year before intensiﬁcation was 7.2% (55 mmol/
mol) and dropped below 7.0% (53 mmol/mol) the year after.
Conclusions: In patients with type 2 diabetes treated in primary care, strict glycaemic control
can be maintained with SUs used as add-on therapy to metformin, without the offset of rele-
vant weight changes.
KEYWORDS
blood glucose, body weight, diabetes mellitus type 2, humans, metformin, prospective
studies, sulphonylurea compounds
1 | INTRODUCTION
Avoiding relevant increases in body weight, particularly after starting
new glucose-lowering agents, is an important treatment target in type
2 diabetes.1 Weight increase in patients with type 2 diabetes is prob-
lematic because it contributes to increased insulin resistance and dis-
ease progression.1–3 In trials investigating new glucose-lowering
agents, body weight is used as a separate endpoint. Except for
lifestyle factors, the various glucose-lowering agents have been
reported to have either decreasing, neutral or increasing effects on
body weight. Among the available agents, metformin is reported to
have no effect on weight,4–6 while several other glucose-lowering
agents have been reported to cause small increases in weight.7–12
The UK Prospective Diabetes Study reported an increase in weight
of ~4 kg in the ﬁrst 3 years after initiation of glibenclamide compared
with metformin, after which weight remained relatively stable.7 The
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A Diabetes Outcome Progression Trial (ADOPT) reported that gliben-
clamide monotherapy caused a 1.6-kg increase in weight in the ﬁrst
year compared with baseline, but remained stable after that for the
next 5 years.13
The magnitude of weight changes in daily practice after starting
sulphonylureas (SUs) is not entirely clear. Only a few observational
cohort studies have investigated the effects of initiation of glucose-
lowering agents on weight; a meta-analysis of just two prospective
studies reported an increase of 2.06 kg [95% conﬁdence interval
(CI) 1.15-2.96] for SUs as a group compared with placebo.14 A retro-
spective cohort study showed that monotherapy with any SU was
associated with a 1.05-kg/m2 (95% CI 0.90-1.20) higher body mass
index 12 months after initiation compared with metformin use.15
It is unclear whether this weight increase is a class effect or
should be attributed to speciﬁc SU drugs. As a consequence, there is
a growing interest in within-class SU differences. Of the SUs availa-
ble, gliclazide has a remarkable safety proﬁle: its use is associated
with exceptionally few hypoglycaemic events.16 Furthermore, glicla-
zide can even be used in patients with renal impairment without dose
adjustment17,18 and is possibly beneﬁcial with respect to cardiovascu-
lar outcomes compared with other SUs.19 Together, this led to the
incorporation of gliclazide as the preferred SU in the Dutch 2013 dia-
betes guidelines when treatment intensiﬁcation after metformin is
required.20 Evidence for within-class differences in weight change
after the start of individual SUs could have consequences regarding
the preferred agent when treatment intensiﬁcation is needed. The
aim of the present study was to investigate within- and between SU-
group weight trajectories, in a prospective primary care cohort of
patients with type 2 diabetes, after starting add-on therapy with indi-
vidual SUs, in addition to metformin.
2 | METHODS
The present study is reported according to the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
recommendations.21
2.1 | Study design and data collection
The present study (part of Clinicaltrials.gov #NCT02133118) was an
analysis of patients included in the prospective Zwolle Outpatient
Diabetes project Integrating Available Care (ZODIAC) study.22 The
ZODIAC study started in 1998 and included patients diagnosed with
type 2 diabetes who were treated exclusively in primary care. Since
then, the ZODIAC study has expanded to more than 600 general
practices in the north-eastern and western part of the Netherlands.
In the Netherlands, all inhabitants have a general practitioner and
>80% of patients with type 2 diabetes are treated exclusively in pri-
mary care.23
As part of the ZODIAC study, the following data are collected by
general practitioners and sent to the diabetes centre annually: pres-
ence of macrovascular complications; diabetes duration; medication
use [diabetes medication, insulin (including type), and all other
medication]; body weight; height (only at baseline); blood pressure;
glycated haemoglobin (HbA1c); serum creatinine; urinary albumin-
creatinine ratio; and lipid proﬁles. All values are measured once at the
yearly check-up with the general practitioner. Any potential changes
within the year were not recorded. All laboratory measurements were
determined using standard laboratory procedures.
2.2 | Patient selection
Eligible for selection were patients with type 2 diabetes, included in
the ZODIAC cohort between 1998 and 2012, who were aged
≥18 years and who received metformin monotherapy during partici-
pation in the ZODIAC cohort, and metformin as monotherapy for at
least 1 year before receiving dual therapy in the form of addition of
an SU in the next year (new-user design).24 Patients were not
excluded on speciﬁc patient characteristics other than age
(<18 years). Data were censored when follow-up ended or when
patients switched medication (including other SUs) during follow-up;
for example monotherapy with an SU or metformin, or when they
subsequently received triple oral therapy or insulin therapy, or at the
end of follow-up, or death, or after 5 years of follow-up. For each
patient the baseline year was deﬁned as the year before treatment
intensiﬁcation with an SU when they were using metformin mono-
therapy. Patients who achieved their HbA1c targets (HbA1c < 7%/
53 mmol/mol) on metformin monotherapy were not included in the
analysis as a comparator group, because this comparator group could
have been subject to selection bias.
2.3 | Outcome measures
The primary outcome of the study was mean yearly change in body
weight compared with weight at baseline for each add-on group sep-
arately for 5 years. Secondary outcome was mean change in HbA1c
compared with baseline.
2.4 | Statistical analysis
Quantitative variables are presented as means with standard devia-
tion for normally distributed values, and median and interquartile
range (IQR) for skewed variables. Pairwise comparisons with one-way
analysis of variance or Kruskal–Wallis tests were Bonferroni-adjusted.
Changes in body weight and HbA1c during follow-up were estimated
using linear mixed models. The use of linear mixed models allowed us
to account for missing data. Patients with missing data on weight or
HbA1c were not excluded; for example, if data on weight was missing
in year 2 but available in year 1 and year 3, the patient was not
included in the analysis in year 2 but was included in years 1 and
3. The changes in weight and HbA1c were modelled with a random
intercept and slope, adjusted for baseline age, gender and diabetes
duration. Age, gender and diabetes duration were modelled as ﬁxed
effects, with age and diabetes duration as continuous variables, while
patients were modelled as a random effect. The model was adjusted
for age, gender and diabetes duration because we hypothesized that
these factors could have inﬂuenced both body weight and the choice
of a speciﬁc SU. All analyses were performed using SPSS 20.0 soft-
ware (SPSS Inc, Chicago, Illinois, USA).
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2.5 | Ethics
In the ZODIAC study, patients consented to anonymous use of their
data for study purposes. The medical ethics committee of Isala,
Zwolle, the Netherlands approved the ZODIAC study (METC refer-
ence numbers 03.0316 and 07.0335).
2.6 | Patient involvement
Patients were not involved in the design of the study, the develop-
ment of outcome measures or in the recruitment of patients.
3 | RESULTS
From the total number of metformin monotherapy users at the start
of the study (n = 29 195), 2958 patients (10.1%) were included in
the analysis. The number of patients at each selection stage is shown
in Figure S1, Supporting Information. Baseline characteristics are
shown in Table 1. The mean age in the four treatment groups ranged
from 62.1 to 63.5 years. Median weight was 91.9 kg in the gliclazide
group, 92.2 kg in the glibenclamide group, 91.3 kg in the glimepiride
group and 89.4 kg in the tolbutamide group.
Baseline weight and HbA1c were available for 520 (99.6%) and
521 (99.8%) patients in the gliclazide add-on group, for 43 (97.7%)
and 43 (97.7%) patients in the glibenclamide add-on group, for
963 (99.8%) and 964 (99.9%) patients in the glimepiride add-on group
and for 1415 (99.2%) and 1427 (100.0%) patients in the tolbutamide
add-on group, respectively.
3.1 | Weight changes during follow-up
The overall results of the linear mixed model analysis showed a non-
signiﬁcant (p = 0.24) linear change in weight during the follow-up
period and a non-signiﬁcant (p = 0.26) difference in weight between
the add-on therapy combinations. In addition, the change in weight
did not signiﬁcantly differ between the add-on therapy combinations
(p value for interaction = 0.67). The regression parameters of the
ﬁxed effects of the mixed model analysis are shown in Table S1, Sup-
porting Information. Estimated weights for the different add-on ther-
apy combinations at yearly time points are shown in Table 2 and
Figure 1A. After 5 years, a non-signiﬁcant increase in weight was
observed in the gliclazide and glibenclamide groups; in the glimepiride
group no change was observed.
3.2 | Glucose control
The HbA1c results showed a non-linear trend over time. A quadratic
trend was introduced in the mixed model analysis for the changes in
HbA1c during follow-up. The results showed a signiﬁcant overall
quadratic trend (p < 0.005) in the HbA1c value during follow-up.
There was no signiﬁcant (p = 0.37) difference between the different
add-on therapy combinations, and a non-signiﬁcant interaction effect
(p = 0.14). In Table S2, Supporting Information the regression para-
meters of the ﬁxed effects of the mixed model analysis are presented.
Estimated HbA1c values for the different add-on therapy combina-
tions at different time periods are shown in Table 3 and Figure 1B. In
the gliclazide, glimepiride and tolbutamide add-on groups, the aver-
age HbA1c levels steadily decreased from 7.1% (54 mmol/mol) and
remained below 7.0% (53 mmol/mol) during the ﬁrst 4 years after
intensiﬁcation, and rose above 7.0% (53 mmol/mol) in the ﬁfth year.
4 | DISCUSSION
In the present study, there was no evidence of a signiﬁcant weight
change within and between the four SU add-on groups in the years
after starting an SU. When used as add-on therapy to metformin,
increases in weight with similar glycaemic efﬁcacy have been
TABLE 1 Demographic and clinical characteristics of patients at baseline
Metformin + glicazide Metformin + glibenclamide Metformin + glimepiride Metformin + tolbutamide
n = 521 n = 43 n = 964 n = 1427
Age at baseline, years 63.1 (11.7) 63.5 (12.3) 62.1 (11.3) 63.5 (11.5)
Gender: women, n (%) 221 (42.5) 21 (50.0) 449 (46.6) 674 (47.2)
HbA1c % 7.1 (6.6-7.6) 7.0 (6.6-7.7) 7.0 (6.6-7.5) 7.0 (6.6-7.5)
mmol/mol 54 (49-60) 53 (54-61) 53 (49-58) 53 (49-58)
n = 522 n = 44 n = 965 n = 1427
Weight, kg 91.9 (90.3, 93.4) 92.2 (86.2, 98.2) 91.3 (90.2, 92.4) 89.4 (88.5, 90.3)
n = 520 n = 43 n = 963 n = 1415
Body mass index 30.9 (5.7) 31.4 (6.1) 30.7 (5.6) 30.2 (5.0)
Systolic blood pressure, mm Hg 140 (17) 140 (14) 139 (17) 138 (16)
Diastolic blood pressure, mm Hg 81 (10) 83 (9) 82 (10) 80 (9)
Cholesterol HDL ratio 3.7 (3.1-4.7) 3.9 (2.8-4.8) 3.7 (3.1-4.6) 3.7 (3.0-4.6)
Creatinine, μmol/L 78 (66-90) 70 (57-83) 76 (65-88) 76 (64-88)
Albumin creatinine ratio 1.0 (0.5-2.9) 0.8 (0.5-1.0) 1.0 (0.4-2.1) 0.8 (0.5-2.0)
Macrovascular complications at
baseline, %
17.8 9.1 14.4 16.7
Diabetes duration, years 3.9 (1.8-5.9) 4.7 (1.3-6.8) 4.0 (2.0-6.3) 4.0 (1.9-6.8)
Data are mean (standard deviation) or median (interquartile range), unless otherwise indicated.
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reported in randomized studies8,10,14,25–27 investigating
glibenclamide,7,26,28 gliclazide,29,30 glimepiride,9 and glipizide.31 Most
studies showed only modest increases in body weight (ranging from
0.5 to 3 kg) and most had a maximum follow-up time of 12 months.
One study with 10 years of follow-up, showed that weight was
gained only in the ﬁrst 3 years after initiation of an SU.26
The present results contrast with results from randomized con-
trolled trials (RCTs). The differences in weight change between this
study and previous RCTs could partly have resulted from differences
in design and baseline factors. Compared with RCTs, the patients
included in the present study differed with respect to glycaemic con-
trol; the average baseline HbA1c level in most RCTs [ranging from
7.3% (56 mmol/mol) to 8.5% (69 mmol/mol)] was higher than the
HbA1c 7.2% (55 mmol/mol) before treatment intensiﬁcation in this
cohort.9,26–32 In addition, patients not only differed with respect to
glycaemic control but probably also according to intensity of patient
visits and patient counselling regarding lifestyle; factors possibly
responsible for the lower average glycaemic control.
These results indicate that it is possible to maintain strict glycae-
mic control in the majority of patients in a real-life setting without
TABLE 2 Estimated mean weight values corrected for age, gender and diabetes duration
Estimated mean weight values, kg (95% CI)
Treatment regimen Metformin + glicazide Metformin + glibenclamide Metformin + glimepiride Metformin + tolbutamide
Year 0 (baseline) 91.8 (90.3, 93.4) 92.2 (86.2, 98.2) 91.3 (90.2, 92.4) 89.4 (88.5, 90.3)
n = 520 n = 43 n = 963 n = 1415
Year 1 91.9 (90.3, 93.5) 92.4 (85.7, 99.1) 91.3 (90.2, 92.4) 89.7 (88.8, 90.6)
n = 510 n = 39 n = 953 n = 1451
Year 2 92.2 (90.4, 93.9) 91.6 (84.6, 98.6) 90.6 (89.4, 91.9) 89.9 (88.9, 91.0)
n = 373 n = 36 n = 681 n = 1009
Year 3 92.1 (90.0, 94.1) 92.7 (84.2, 101.2) 91.0 (89.4, 92.6) 89.6 (88.3, 90.8)
n = 243 n = 26 n = 434 n = 657
Year 4 93.0 (90.2, 95.8) 92.4 (81.7, 103.2) 90.8 (88.6, 93.0) 89.9 (88.2, 91.7)
n = 147 n = 16 n = 244 n = 364
Year 5 95.7 (92.1, 99.3) 95.5 (84.5, 106.4) 91.4 (88.4, 94.4) 90.8 (88.3, 93.3)
n = 94 n = 13 n = 148 n = 206
FIGURE 1 (A) Estimated mean body weight (kg) during follow-up. Adjusted for age, gender and diabetes duration. (B) Estimated mean HbA1c
(%) during follow-up. Adjusted for age, gender, diabetes duration. Horizontal line indicates the treatment target at the time the study was
performed.
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relevant weight increases when starting an SU. The effects of SUs on
weight appear to be different from the effects found in observational
studies. In such studies, signiﬁcant or relevant weight increases have
only been reported in people with unfavourable glycaemic control at
baseline and only when SUs were analysed as one group.32,33 Based
on the CIs, however, we cannot exclude the possibility that there was
a small weight increase in the present study. In contrast with previous
observational studies, glycaemic control in patients included in the
ZODIAC cohort was excellent.34 Moreover, when interpreting weight
changes in observational cohort studies, there are several other possi-
ble explanations for weight increase besides the effects of medica-
tion. In the general population aged 55-65 years, an increase of
several decigrams per year is a phenomenon that is observed in sev-
eral population studies performed in middle- and high-income coun-
tries and therefore is not necessarily related to diabetes
medication.35,36
In the Netherlands, a form of protocol-based care is deployed,
which probably could be an explanation for the on average small and
seemingly non-relevant decrease in HbA1c. At the time the study
was performed, patients treated in the Netherlands were checked at
least once a year by their general practitioner and three times a year
by practice nurses. During these visits there is a strong focus on life-
style advice as well as glycaemic control.20 When patients’ HbA1c
levels are above target, treatment is immediately intensiﬁed, even
when they are only slightly above target. In the RCTs no structured
lifestyle advice was described in the methods sections. Non-
adherence to lifestyle advice has been associated with worsening gly-
caemic control and weight gain,37–39 with subsequent increases in
HbA1c leading to treatment intensiﬁcation.40
The sample used in the present study has a high degree of gener-
alizability and represents the majority of primary care-treated
patients in the Netherlands. Large regions of the Netherlands are par-
ticipating in projects similar to that included the present study, and all
patients with type 2 diabetes have the opportunity to opt out. In the
Netherlands all patients have a primary care physician and >80% of
all patients with type 2 diabetes are treated exclusively in primary
care.23 In contrast to the observational design of the present study,
RCTs often have strict selection criteria, limiting the number of
patients eligible for inclusion and possibly leading to sample selection
bias and therefore complicating the generalizability to daily
practice.41
Strengths of the present study include the number of patients,
the daily care setting and the new-user design, thereby avoiding two
potential types of bias: underascertainment of weight changes that
occur early after the start of add-on therapy and the inability to con-
trol for disease risk factors that may be altered by the study drugs
themselves.24 Furthermore, >97% of all observations on weight and
99% of all observations on HbA1c from any study visit were com-
plete at baseline and during follow-up. The outcome measures weight
and HbA1c were missing for a small percentage of patients but this
posed no problem when using linear mixed models because all miss-
ing values are caused by random omissions in the registration and are
consequently ‘missing completely at random.’ The decrease in the
number of patients can mostly be explained by the study design.
Patients entered the ZODIAC cohort at different time points and also
entered into the present study at different time points; for example, a
patient who entered the study in 1998 could have a maximum
follow-up of 6 years, while a patient who entered in 2009 could only
have 3 years of follow-up as the study cohort was censored at
December 31, 2012. In addition, for a patient included in the
ZODIAC cohort the maximum length of follow-up was also shortened
if this patient has, for example, 3 years of metformin monotherapy
before receiving an add-on, because in the present study follow-up
started in the year before receiving the add-on. Table S5, Supporting
Information shows the number of people censored because of
changes in medication during follow-up.
The study also has some important limitations. Although there
were no signiﬁcant within-class differences in weight change after
starting SUs in the ﬁrst 5 years after treatment intensiﬁcation, the
number of patients in the gliclazide and glibenclamide group was
small and a potentially relevant increase in weight could not be
excluded. Furthermore, the decrease in number of patients in the tol-
butamide and glibenclamide groups was relatively high compared
with the other groups.
TABLE 3 Estimated mean HbA1c values corrected for age, gender and diabetes duration
Estimated mean HbA1c values, % (95% CI)
Treatment regimen Metformin + glicazide Metformin + glibenclamide Metformin + glimepiride Metformin + tolbutamide
Year 0 (baseline) 7.21 (7.18, 7.24) 7.19 (7.08, 7.29) 7.18 (7.16, 7.20) 7.15 (7.14, 7.17)
n = 521 n = 43 n = 964 n = 1427
Year 1 7.02 (6.99, 7.05) 7.12 (7.00, 7.24) 6.99 (6.97, 7.02) 7.02 (6.99, 7.03)
n = 512 n = 39 n = 953 n = 1459
Year 2 6.92 (6.88, 6.95) 7.02 (6.88, 7.15) 6.89 (6.86, 6.92) 6.93 (6.90, 6.95)
n = 374 n = 36 n = 681 n = 1014
Year 3 6.90 (6.85, 6.95) 7.06 (6.88, 7.23) 6.89 (6.85, 6.92) 6.91 (6.88, 6.94)
n = 243 n = 26 n = 435 n = 659
Year 4 6.92 (6.84, 6.99) 7.11 (6.85, 7.36) 6.98 (6.92, 7.04) 6.90 (6.86, 6.95)
n = 147 n = 16 n = 245 n = 364
Year 5 7.12 (6.99, 7.24) 7.31 (6.97, 7.65) 7.18 (7.10, 7.26) 7.01 (6.94, 7.08)
n = 94 n = 13 n = 149 n = 206
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Secondly, baseline macrovascular complications differed between
the SU groups. Although the Dutch diabetes guidelines do not base
the choice of an oral glucose-lowering agent on the presence of
macrovascular complications, this theoretically could have inﬂuenced
the choice of SU; however, the post hoc sensitivity analysis
(Tables S3 and S4, Supporting Information) showed that the addition
of macrovascular complications did not relevantly change the results.
Third, the quality and reliability of our data were dependent on the
accuracy of the data provided by practice nurses and general practi-
tioners as part of a yearly benchmark. Information on doses and
adherence to medication was not recorded within the ZODIAC
cohort. Because data on medication adherence were not available,
patients could have stopped medications during the following year
which could possibly have resulted in misclassiﬁcation. In addition, as
patients may have been prescribed an SU at different time points
during the year, the time between the ﬁrst prescription of an SU and
the measurement of body weight varied and was not always 1 year;
however, there was no reason to assume that adherence and time of
initiation within the year would substantially differ between groups.
Furthermore, it is possible that patients who started to gain weight
while using an SU wanted to try a different drug; however, we have
no evidence that this is the case (Table S6, Supporting Information).
The rapid decrease in number of patients after year 2 could compli-
cate the interpretation of the results, but in the present study the CIs
remain narrow. A common side effect of SUs as a group is severe
hypoglycaemic events, which were not recorded in our database;
however, the hazard of severe hypoglycaemia is very limited in
gliclazide users,16 the most prescribed SU in the Netherlands.
Furthermore, as no signiﬁcant differences in weight were found, a
dose–response analysis was not performed.
In conclusion, there was no evidence of relevant within-class SU
differences in weight during follow-up. The results of the present
study support the view that strict glycaemic control can be main-
tained in a substantial proportion of the primary care patients in the
Netherlands with type 2 diabetes without clinically relevant weight
change when adding SUs to metformin. In real life, when weight gain
does occur, factors other than medication effects, for example,
lifestyle-associated factors, are likely to be more important.
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